SAN DIEGO, June 18, 2008 (PRIME NEWSWIRE) -- TRACON Pharmaceuticals, Inc., announced that the first cancer patient has been treated in a Phase 1 clinical trial with oral TRC102, a novel anti-cancer drug intended to reverse resistance to Alimta(r) chemotherapy by targeting a specific DNA repair pathway.
